Search research articles
Contact Us
Filters
Showing results (21-30 of 41) with videos related to
Page
of 5
Sort By:
Revue Des Maladies Respiratoires
|
June 12, 2012
[The Lady Windermere syndrome: clinical and bacteriological data and progress in seven cases]
F Bonnaud, S-K Adjoh, P Wachinou, et al.
Revue Des Maladies Respiratoires
|
January 1, 1989
[Post-traumatic pulmonary hematomas. Apropos of 2 cases]
B Melloni, A Vergnenegre, F Bonnaud, et al.
Revue Des Maladies Respiratoires
|
November 19, 2005
[Indoor radon exposure and lung cancer risk. Results of an epidemiological study carried out in France]
H Baysson, M Tirmarche, G Tymen, et al.
Anti-Cancer Drugs
|
February 1, 1995
Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group
M Marty, J P Kleisbauer, P Fournel, et al.
Bulletin Du Cancer
|
January 1, 1995
[Carboplatin-VP16 combination in non small cell lung cancers in the aged patient. A study of the French group in pneumology (GFPC)]
O Castelnau, M Pérol, A Vergnenegre, et al.
Revue Des Maladies Respiratoires
|
May 2, 2008
[Age and management decisions in patients with primary lung cancer]
S Yonnet, V Gazaille, M Grasset-Dupuy, et al.
Critical Reviews in Oncology/Hematology
|
August 3, 2007
An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a study
H LeCaer, P Fournel, H Jullian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 27, 2006
Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01)
A Vergnenegre, C Combescure, P Fournel, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 13, 2012
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study)
H LeCaer, L Greillier, R Corre, et al.
Bulletin Du Cancer
|
April 26, 2000
[Phase II study of docetaxel in inoperable advanced non small cell lung cancer]
G Robinet, P Thomas, M Pérol, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 41) with videos related to
Sort By:
Page
of 5
Revue Des Maladies Respiratoires
|
June 12, 2012
[The Lady Windermere syndrome: clinical and bacteriological data and progress in seven cases]
F Bonnaud, S-K Adjoh, P Wachinou, et al.
Revue Des Maladies Respiratoires
|
January 1, 1989
[Post-traumatic pulmonary hematomas. Apropos of 2 cases]
B Melloni, A Vergnenegre, F Bonnaud, et al.
Revue Des Maladies Respiratoires
|
November 19, 2005
[Indoor radon exposure and lung cancer risk. Results of an epidemiological study carried out in France]
H Baysson, M Tirmarche, G Tymen, et al.
Anti-Cancer Drugs
|
February 1, 1995
Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group
M Marty, J P Kleisbauer, P Fournel, et al.
Bulletin Du Cancer
|
January 1, 1995
[Carboplatin-VP16 combination in non small cell lung cancers in the aged patient. A study of the French group in pneumology (GFPC)]
O Castelnau, M Pérol, A Vergnenegre, et al.
Revue Des Maladies Respiratoires
|
May 2, 2008
[Age and management decisions in patients with primary lung cancer]
S Yonnet, V Gazaille, M Grasset-Dupuy, et al.
Critical Reviews in Oncology/Hematology
|
August 3, 2007
An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a study
H LeCaer, P Fournel, H Jullian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 27, 2006
Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01)
A Vergnenegre, C Combescure, P Fournel, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 13, 2012
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study)
H LeCaer, L Greillier, R Corre, et al.
Bulletin Du Cancer
|
April 26, 2000
[Phase II study of docetaxel in inoperable advanced non small cell lung cancer]
G Robinet, P Thomas, M Pérol, et al.
Page
of 5